HOLLIS EDEN PHARMACEUTICALS INC /DE/
S-3, EX-5.1, 2000-12-05
PHARMACEUTICAL PREPARATIONS
Previous: HOLLIS EDEN PHARMACEUTICALS INC /DE/, S-3, 2000-12-05
Next: HOLLIS EDEN PHARMACEUTICALS INC /DE/, S-3, EX-23.1, 2000-12-05



<PAGE>

                                                                    EXHIBIT 5.1

[LETTERHEAD OF COOLEY GODWARD LLP]

December 5, 2000

Hollis-Eden Pharmaceuticals, Inc.
9333 Genesee Avenue, Suite 110
San Diego, CA 92121

Ladies and Gentlemen:

  You have requested our opinion with respect to certain matters in connection
with the filing by Hollis-Eden Pharmaceuticals, Inc., a Delaware corporation
(the "Company"), of a Registration Statement on Form S-3 (the "Registration
Statement") and related Prospectus, covering the registration of 228,672
shares of the Common Stock of the Company (the "Shares") on behalf of certain
selling stockholders.

  In connection with this opinion, we have examined and relied upon the
Registration Statement and related Prospectus, the Company's Certificate of
Incorporation and Bylaws, as amended, and the originals or copies certified to
our satisfaction of such records, documents, certificates, memoranda and other
instruments as in our judgment are necessary or appropriate to enable us to
render the opinion expressed below. We have assumed the genuineness and
authenticity of all documents submitted to us as originals, the conformity to
originals of all documents submitted to us as copies thereof and the due
execution and delivery of all documents where due execution and delivery are a
prerequisite to the effectiveness thereof.

  On the basis of the foregoing, and in reliance thereon, we are of the
opinion that the Shares are validly issued, fully paid and nonassessable.

  We consent to the reference to our firm under the caption "Legal Matters" in
the Prospectus included in the Registration Statement and to the filing of
this opinion as an exhibit to the Registration Statement.

                                          Very truly yours,

                                          Cooley Godward LLP

By: /s/ Thomas A. Coll
    Thomas A. Coll


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission